The Effect of Caffeine on the Narcoleptic Patients

King Saud University

Status and phase: Completed; Phase 2; Phase 1

Conditions: Narcolepsy

Treatments: Drug: Fiber; Drug: Vivarin

Study type: Interventional

Funder types: Other

Identifiers

NCT02832336

SFDA # 16022302 (Registry Identifier)

IRB:E-15-1484

Details and patient eligibility

About

Caffeine may be playing a beneficial role in patients with narcolepsy. However, the relationship between caffeine and its effects on narcoleptic patients has not been examined, and it is also unclear whether caffeine provides a beneficial effect or not. Hence, the aim of this study is to assess the effects of caffeine consumption on daytime sleepiness and reaction time in narcoleptic patients.

Full description

The participants will be recruited at the University Sleep Disorders Center, College of Medicine, King Saud University.

Narcolepsy diagnosis: Narcolepsy will be diagnosed based on the American Academy of Sleep Medicine International Classification of Sleep Disorders, 2014 (American academy of sleep medicine. International classification of sleep disorders (ICSD), 3rd ed. Darien, il: American academy of sleep medicine, 2014).

The study will be interventional, randomized, double-blind, placebo control study, to evaluate the effect of caffeine on Narcoleptic Adults (n=30) aged 18-45 years old, following up in the Sleep Disorders Center (SDC) at King Khalid University Hospital (KKUH).

Tools of the study:

The study tools included an interview questionnaire, anthropometric measurements, indirect calorimetry, body composition measurements, blood biochemistry tests & Eye Blink measurement.

1. Interview Questionnaire:

   For collecting data for this study, questionnaire well be designed.

   The questionnaire consisted of four parts to elicit the following information:

   A) Socio-demographic Data

   • Personal data: The name of the participant, age, sex, educational level, and residence.
   • Social habits: The smoking status
   • Activity level: Mild, moderate or intense physical activity.

   B) Medical information:

   • The occurrence of Narcolepsy with or without cataplexy.
   • The occurrence of chronic diseases (hypertension, hyperlipidemia, cardiac diseases, diabetes and obesity).

   C) Caffeine expectancy & consumption, modified from:

   • Caffeine expectancy questionnaire (CaffEQ) is a self-report measure, which assesses a range of expectancies for caffeine, and Sleep Disturbance (Huntley & Juliano, 2007).
   • The Caffeine Consumption Questionnaire (CCQ) used to produce a typical week's average estimate of caffeine consumption in milligrams (Heaton, 2010).

   D) Daytime sleepiness Scales :

   • Stanford Sleepiness Scale (SSS)
   • The Karolinska Sleepiness Scale (KSS)

2. Anthropometric measurements:

   The four selected anthropometric measures, see below:

   • Weight
   • Height for calculating body mass index (BMI)
   • Waist circumference
   • Hip circumference

3. Indirect calorimetry An automated metabolic measuring cart used for determining Energy Expenditure and for providing key information about the nutrient mixture catabolized for energy by measuring the rates of O2 consumption (VO2) and CO2 production (VCO2), the device name is QUARK.

4. Body Composition Measurement:

   The five variables selected for body composition measurements are:

   • Fat mass
   • Muscle mass
   • Bone mass
   • Total body water
   • Visceral fat rating The body composition machine will be used is Bioelectrical impedance analysis (Tanita BC-418, Japan).

5. Blood biochemistry tests:

   Fasting blood glucose, lipids Profile, CBC, LFT, CRP, Bone Profile, Vit D. Biochemical measurements will be done at KKUH, it is equipped with all needed matching to run this study and has well-trained technician and statics to help in performing the test needed.

6. Eye Blink Measurement. Setting/Procedure

In the day of study, subject need to come fasting overnight so their fasting blood glucose levels and lab test sample will be taken. Then the Anthropometric, Body Composition & Indirect calorimetry Measurement for the subject will be documented. The sample will be randomly divided using a software and the tablets will be identically packaged by the pharmacist in opaque capsules and administered orally in a double- blind setting to one of the following Groups:

• Group one: will receive 200 mg Caffeine capsule + water.
• Group two: will receive Placebo (fiber capsule) + water.

Then instruct the patients to take the medication/placebo in the morning for 1 week and come back for reassessment:

• Random Blood sugar will be taken
• Blood Pressure will be measured.
• Eye Blink Measurement
• Daytime sleepiness Scales (part of the questioner data will be filled) We will have a baseline assessment, 1st assessment after single dose of 200 mg Caffeine or placebo and second assessment after one week of chronic use of medication in a dose 200 mg During the patient waiting time, the Interview Questionnaire will be filled.

Data management:

Data will be categorized to age, sex, social, anthropometric measurements, biochemistry lab test, psychological and medical status.

Statistical analysis Data will be entered and statistically analyzed by SPSS software. ANOVA will be used to differentiate among treatment groups. In all the statistical comparisons, differences with p < 0.05 will be considered to be significant.

Steps for assuring data quality include:

• Training: Educate data collectors in a structured manner.
• Data completeness: Using the hospital program (Cerner) that give immediate feedback on issues such as missing or out-of-range values & Excel software
• Data consistency: Compare across sites and over time.
• Data dictionary will be used e.g World Health Organization Drug Dictionary, Cerner program record for normal ranges.

Ethical consideration The study was approved by KKUH Ethical committee, Saudi Food & Drug Authority & Saudi Clinical Trial Registry.

Enrollment: 16 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Case -group should be Narcoleptic with cataplexy

Exclusion criteria

• Individuals older than 45 years or younger than 18 years old.
• Individuals complaining of any diseases or conditions that affect their dietary intake, as such : renal failure, liver failure, malabsorption problems, cardiac diseases ... etc.
• Individuals having hypersensitivity to caffeine.
• Individuals with medical conditions that cause sleepiness (like hypothyroidism) and pregnant or lactating females will be excluded.

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

16 participants in 2 patient groups, including a placebo group

Caffeine

Experimental group

Description:

Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakefulness state. Generic name :Vivarin(1,3,7-trimethylxanthine), 200 mg/day for one week, Form of Administration:Oral in veg white capsule form (size 1) Drug Class:Central nervous system (CNS) stimulants.

Treatment:

Drug: Vivarin

Fiber

Placebo Comparator group

Description:

Fiber powder will be used as placebo, Form of Administration:Oral in veg white capsule form (size 1)

Treatment:

Drug: Fiber